Management | MediMergent

The Management Team

Sandra Garrett, PhD

Chief Executive Officer

Representing the Voice of the Patient

Serial Healthcare Technology Entrepreneur, FDA Partner, Innovator

Dr. Sandra Garrett is the Chief Executive Officer of MediMergent, LLC. Prior to co-founding the Company, she served as the Chief Executive Officer of Global Records Systems, LLC, an Electronic Medical Records (EMR) service and software company. Previously, Dr. Garrett served as Executive Chairman of Global Research Services, LLC, a full service international clinical research organization (CRO) with offices on 3 continents. Dr. Garrett was also the founder of Medifacts International and served as its President and CEO until 2006. Medifacts pioneered the use of 24-hour ambulatory blood pressure monitoring in clinical trials. The Company also pioneered, in alliance with the Max Planck Institute, algorithms for the analysis of QT prolongation as measured by ambulatory 12-lead electrocardiogram (Holter) monitoring. In conjunction with these technologies, Dr. Garrett served as the co-principal investigator with Raymond Lipicky, MD (decd), a past director of the Division of Cardio-Renal Drug Products of the USFDA, under a Cooperative Research and Development Agreement (CRADA). This landmark research defined critical analytics used in the drug approval process for all anti-hypertensive therapies. Dr. Garrett currently serves as the co-principal investigator with Norman Stockbridge, MD, Ph.D., Director of the Division of Cardiovascular and Renal Drug Products, USFDA, under a Research Collaboration Agreement (RCA) focused on the collection and analysis of Real-World Data and Real-World Evidence using disruptive technologies.

Dr. Garrett has been an invited speaker at over 100 industry forums, authored multiple publications related to clinical trials methodologies, and served as co-chair of the annual New Paradigms to Fund Life Science Innovations, conducted in conjunction with the JP Morgan Health Care Conference. Dr. Garrett served on the Board of Directors of a regional bank as well as the Board of the Association of Clinical Research Organizations (ACRO). In addition, she was a finalist for the Ernst & Young Entrepreneur of the Year award in the area of Life Sciences, and a three-time honoree by Women in Bio (WIB) for notable women entrepreneurs in life sciences. SmartCEO selected Dr. Garrett as one of the top 50 businesswomen in Washington, D.C.

She is presently a member of the Leadership Council of the National Small Business Association and serves on its Health and Human Resource Committee.

Dr. Garrett received her MA and PhD from the University of Massachusetts and MBA from the University of Dallas.

Adam Duritza

Chief Technology Development Advisor

Representing the Voice of Technology

Marketing and Business Strategist, Product Manager and Social Media Expert

Adam Duritza is the Chief Technology Development Advisor for MediMergent, LLC. His experience includes serving as the Chief Development Officer at System1 where he is responsible for M&A, Partnerships and Growth in a leading consumer internet and applications business with 50+ content and search properties that reach over 120 million consumers each month. He is also responsible for leading product distribution partnerships for top software, app and search providers. Prior to this position, he was the Chief Executive Officer of Homescore which re-invented home searches with AI and Machine Learning using millions of data points to help find the perfect home. In addition, as the Strategy and Business Development Advisor to Manchester United, Adam advised the CEO of media strategy and facilitated key partnerships with both tech platforms and traditional media for Manchester United’s direct-to-consumer media business.

From 2014 to 2017 Adam worked at Yahoo Inc. as Head of Video where he created and led a team which distributed Yahoo’s content to 1,000+ apps, sites and platforms and directed content acquisition efforts with studios, networks and streaming services.

From 2011 to 2014 while at Yahoo, Inc. he was the GM, Yahoo Autos, Travel and Real Estate and directed activities of a global team across 6 offices including Business Development, Product, Editorial, and Marketing. He was a Principal at Spotlight Analytics from 2009 to 2011 where he was part of the founding team of an analytics advisory firm to top media and entertainment companies and engagements included the launch of groundbreaking new Premium VOD service for a top film studio as well as several innovative theme park marketing strategies. He was an Engagement Manager for Marakon, a premier strategy consulting firm that partners with CEO teams of Fortune 200 companies to drive value transformation. In this position he was responsible for leadership of strategy consulting teams and advised the executive teams of some of the largest companies in the world on their corporate value growth and M&A strategy.

A Merit Scholar, after graduation from Northwestern University, Adam was hired at Thomson Reuters – Hubbard One as a lead software developer and technical architect for multiple web-based applications in the Legal and Financial Services industries. Adam has been awarded the 2015 and 2016 Yahoo Excellence Award as well as awards at Yahoo for performance in the top 10% in 2016 and 2017.

Greg Simon

President

Representing the Voice of the Patient

Lawyer, Policy Analyst, Patient Advocate, Global Speaker

Greg Simon is the President of MediMergent, LLC and responsible for all strategy related to the collection and analysis of Real World Data for Pharma, Payers, Prescribers and Regulators. He is a knowledgeable analyst of emerging trends in healthcare, information technology, innovative drug research and development and patient advocacy.

He previously was the President of the Biden Cancer Initiative at the Biden Foundation. While at the Biden Foundation, Greg and his team worked across the Task Force, academia and the private sector to create over seventy innovative collaborations.

Prior to this position, he was the Executive Director of the White House Cancer Moonshot Task Force, a position created by President Barack Obama and for which he was chosen by Vice President Joe Biden in March 2016. As Executive Director, Greg assembled and led a team of eight professionals to support the work of the Vice President in developing and promoting the goals of the Cancer Moonshot in numerous meetings and presentations and to coordinate the work of the Task Force comprised of twenty cabinet and sub-cabinet offices.

Before becoming Executive Director of the Cancer Moonshot, Greg was the CEO of Poliwogg, a financial services company creating unique capital market opportunities in healthcare and life sciences. Poliwogg’s first index, the Poliwogg Medical Breakthroughs Index, was the basis for the best performing health Exchange Traded Fund, “SBIO,” in 2015.

In his career, Greg has held senior positions in both chambers of Congress, was Chief Domestic Policy Advisor to Vice President Al Gore, was a senior strategy consultant to a variety of international technology CEO’s, co-founded and led FasterCures and the Melanoma Research Alliance, was the Senior Vice President at Pfizer for worldwide policy and public engagement.

The journal Nature Medicine named Greg one of “Ten People to Watch” in health care policy, noting that he was among “a handful of influential people who quietly keep the wheels of biomedical science turning.” In 2010 he received the Genetic Alliance’s “Art of Advocacy” award. In May 2011 Greg was invited to be the second lecturer in the Constantin Spiegelfeld Lecture series of the Research Center for Molecular Medicine of the Austrian Academy of Sciences. He is the recipient of the Arab American Institute’s 2017 Najeem Halaby Public Service Award established by Queen Noor in memory of her father. He is a regular presenter at the Milken Institute Global Conference, the OECD, the Washington Campus (a nonprofit educational institution in Washington, D.C.) and at health conferences and academic institutions around the country.

He received his law degree from the University of Washington in 1983 where he was a member of the Law Review and the Moot Court. He has a B.A. in history from the University of Arkansas.

Kenneth Borow, MD

Chief Medical Officer

Representing the Voice of Pharma

Physician, Clinical Trialist, Healthcare Entrepreneur

Dr. Ken Borow is a highly experienced clinician, clinical investigator and trialist. He is a Harvard-trained adult cardiologist, pediatric cardiologist, internist and pediatrician with over 30 years of clinical research experience. As a faculty member at Harvard Medical School and, subsequently, Professor of Medicine and Pediatrics at the University of Chicago, he is the author of more 120 publications across multiple therapeutic areas. As Director of the Cardiovascular Non-Invasive Imaging Program at the University of Chicago, he was responsible for clinical and research studies involving multiple advanced imaging techniques. He also oversaw a large research group focused on ischemic heart disease and heart failure that included centers in North America, the United Kingdom, Norway, Israel, and South Africa. For nearly a decade, Dr. Borow worked closely with the world-renowned pioneering cardiac surgeon Professor Sir Magdi Yacoub on issues relating to heart failure as well as heart and heart/lung transplantation. He was a senior member of the National Heart Lung and Blood Institute (NHLBI) Task Force on Heart Failure which was chaired by Dr. Eugene Braunwald. The Task Force Report was used as the foundation for NHLBI funding priorities for heart failure research from the late 1990s and into the 21st Century. Dr. Borow’s biopharmaceutical industry experience includes responsibility for Clinical Research Operations in the U.S. and Puerto Rico for Merck Research Laboratories. In this role, he was actively involved in the clinical development of 38 new drug entities. Subsequently, Dr. Borow was CEO of a NASDAQ-traded contract research organization (CRO) with operations in 30 countries. He led the company’s consulting business, was actively involved in the design and conduct of multiple international clinical trials, and helped build the Company into an internationally recognized provider of quality consulting and clinical operational services.

In his career, Dr. Borow has been actively involved in the design and operationalization of over 100 development programs for drugs, biologics, medical devices, and combination products. He has had broad involvement with Data Safety Monitoring Boards (DSMB) as well as Clinical Endpoints Committees (CEC). He has extensive experience with the FDA as well as EMA. He has been a senior advisor to a myriad of biopharmaceutical companies as well as numerous prominent venture capital firms around the world. He holds multiple patents relating to the development of drugs, biologics and medical devices.

Bruce Garrett, MD

Chief Operating Officer

Representing the Voice of the Prescriber

Physician, Operations Specialist, Strategist